论文部分内容阅读
目的对不同药物治疗恶性血液病合并侵袭性真菌感染的临床疗效进行分析。方法选取2011年2月~2012年12月唐山市开滦总医院200例恶性血液病合并侵袭性真菌感染的患者。随机分为卡泊芬净组(A组)、伏立康唑组(B组)、伊曲康唑组(C组)、两性霉素B组(D组)、卡泊芬净联合伏立康唑治疗组(E组),每组各40例。对五组患者治疗后的临床疗效进行分析。结果 A,B,C,D和E组总有效率分别为80.0%(32/40),90.0%(36/40),87.0%(35/40),96.0%38/40)和96.0%(38/40)。E组治疗效果较为突出,在临床治疗有效率方面与A组、C组、D组治疗相比差异具有统计学意义(P<0.05)。结论卡泊芬净联合伏立康唑在治疗恶性血液病合并侵袭性真菌感染方面较单一用药治疗疗效更佳,可在临床推广应用。
Objective To analyze the clinical efficacy of different drugs in the treatment of patients with hematologic malignancies complicated with invasive fungal infection. Methods From February 2011 to December 2012, 200 patients with malignant hematological disease complicated with invasive fungal infection were admitted to Kailuan General Hospital of Tangshan City. Randomized into caspofungin group (group A), voriconazole group (group B), itraconazole group (group C), amphotericin group B (group D), caspofungin combined with voriconazole treatment group Group), 40 cases in each group. Five groups of patients after treatment of clinical efficacy analysis. Results The total effective rates in group A, B, C, D and E were 80.0% (32/40), 90.0% (36/40), 87.0% (35/40), 96.0% 38/40 and 96.0% 38/40). The treatment effect of group E was prominent, and there was significant difference (P <0.05) in the clinical treatment efficiency compared with group A, group C and group D treatment. Conclusion Caspofungin combined with voriconazole in the treatment of hematologic malignancies associated with invasive fungal infection is better than the single drug treatment efficacy, which can be popularized in clinical application.